Abstract
Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Mini-Reviews in Medicinal Chemistry
Title: Small Interfering RNA for Effective Cancer Therapies
Volume: 11 Issue: 2
Author(s): X. Wang, Y. Chen, J. Ren and X. Qu
Affiliation:
Keywords: Small interfering RNA, pharmacodynamics, cancer, oncogene, apoptosis, cell cycle, angiogenesis, multidrug resistance, oncogenes, cyclins, anti-apoptotic genes, Carcinogenesis Pathways, Viral Oncogenes, Radiotherapy/Chemotherapy Resistance
Abstract: Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Export Options
About this article
Cite this article as:
Wang X., Chen Y., Ren J. and Qu X., Small Interfering RNA for Effective Cancer Therapies, Mini-Reviews in Medicinal Chemistry 2011; 11 (2) . https://dx.doi.org/10.2174/138955711794519528
DOI https://dx.doi.org/10.2174/138955711794519528 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Angiogenic Properties of Primary Cells Intended at Bone Regeneration: A Comparison to Differentiated Cells Using the CAM Assay
Current Angiogenesis (Discontinued) Ectopic Thyroid Gland: Description of a Case and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Radiosensitizing Potential of Epigenetic Anticancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Animal Mitochondria: Evolution, Function, and Disease
Current Molecular Medicine Preparation and Primary Bioevaluation of 99mTc-labeled-1-thio-β-D-Glucose as Melanoma Targeting Agent
Current Radiopharmaceuticals Circadian Timekeeping in Anticancer Therapeutics: An Emerging Vista of Chronopharmacology Research
Current Drug Metabolism Cross Bridging Proteins in Nature and their Utilization in Bio- and Nanotechnology
Current Protein & Peptide Science Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine Strategies for the Assessment of Metabolic Profiles of Steroid Hormones in View of Diagnostics and Drug Monitoring: Analytical Problems and Challenges
Current Drug Metabolism An Overview of Emerging Immunotargets of Genitourinary Tumors
Current Drug Targets Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Reducing False Positive Findings in Statistical Analysis of Pharmacogenomic Biomarker Studies Using High-Throughput Technologies
Current Drug Safety Synthetic Src-Kinase Domain Inhibitors and Their Structural Requirements
Anti-Cancer Agents in Medicinal Chemistry Journey of 2′-deoxy-2′-fluoro-5-methyl-1-β-D-arabinofuranosyluracil (FMAU): from Antiviral Drug to PET Imaging Agent
Current Medicinal Chemistry ABC Transporters and Drug Resistance in Patients with Epilepsy
Current Pharmaceutical Design Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters The Use of Technetium-99m Radiolabeled Human Antimicrobial Peptides for Infection Specific Imaging
Mini-Reviews in Medicinal Chemistry Mirna Expression in Bladder Cancer and Their Potential Role in Clinical Practice
Current Drug Metabolism Tackling Chronic Pain and Inflammation through the Purinergic System
Current Medicinal Chemistry